The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium is a peripherally ...
The anti-xerostomia effects of muscarinic agonists (cholinomimetics) are reviewed. Cevimeline (cevimeline monohydrochloride hemihydrate) is a novel muscarinic agonist that stimulates salivary ...
Researchers from Cerevel Therapeutics LLC presented data from a study that aimed to evaluate preclinical antipsychotic properties of M4 agonism while minimizing off-target side effects using novel ...
In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...
The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a pivotal moment in the treatment of schizophrenia. KarXT, an oral dual M1/M4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results